Ming Li

ORCID: 0000-0002-3855-0724
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Extracellular vesicles in disease
  • Nanoplatforms for cancer theranostics
  • Heat shock proteins research
  • interferon and immune responses
  • Quantum Dots Synthesis And Properties
  • Animal Nutrition and Physiology
  • RNA Interference and Gene Delivery
  • Cell Adhesion Molecules Research
  • Vector-borne infectious diseases
  • Ion Channels and Receptors
  • Inhalation and Respiratory Drug Delivery
  • Protease and Inhibitor Mechanisms
  • Herpesvirus Infections and Treatments

Soochow University
2022-2024

Changshu No.1 People's Hospital
2024

Northeast Agricultural University
2014

Daqing Normal University
2014

Abstract The survival of malignant tumors is highly dependent on their intrinsic self-defense pathways such as heat shock protein (HSP) during cancer therapy. However, precisely dismantling self-defenses to amplify antitumor potency remains unexplored. Herein, we demonstrate that nanoparticle-mediated transient receptor potential vanilloid member 1 (TRPV1) channel blockade potentiates thermo-immunotherapy via suppressing factor (HSF1)-mediated dual pathways. TRPV1 inhibits...

10.1038/s41467-023-38128-x article EN cc-by Nature Communications 2023-04-29

Abstract Background Hematological metastasis has been recognized as a crucial factor contributing to the high rates of and mortality observed in colorectal cancer (CRC). Notably, exosomes derived from cells participate formation CRC pre-metastatic niches; however, mechanisms underlying their effects are largely unknown. While our preliminary research revealed role exosome-derived disintegrin metalloproteinase 17 (ADAM17) early stages metastasis, exosomal ADAM17 hematogenous remains unclear....

10.1186/s13046-024-02991-3 article EN cc-by Journal of Experimental & Clinical Cancer Research 2024-02-27

Oral squamous cell carcinoma (OSCC) contributes to more than 90% of all oral malignancies, yet the performance traditional treatments is impeded by limited therapeutic effects and substantial side effects. In this work, we report a combinational treatment strategy based on tumor exosome-based nanoparticles co-formulating photosensitizer (Indocyanine green) tyrosine kinase inhibitor (Gefitinib) (IG@EXOs) for boosting antitumor efficiency against OSCC through synergistic phototherapy-molecular...

10.3390/pharmaceutics16010033 article EN cc-by Pharmaceutics 2023-12-26
Coming Soon ...